Bank of New York Mellon Corp Invests $13.41 Million in Oruka Therapeutics, Inc. $ORKA

Key Points

• Bank of New York Mellon purchased 140,870 Oruka Therapeutics shares worth approximately $13.41 million, giving it a 0.23% stake. Institutional investors collectively own 56.44% of the company.
• Analyst sentiment remains broadly positive, with 10 Buy ratings and one Sell rating; Oruka has a consensus “Moderate Buy” rating and an average price target of $134.30 versus a recent price of $92.11.
• ORKA shares were down 0.6%, while the company reported a quarterly loss of $0.55 per share, missing estimates by $0.04. Insiders sold 158,116 shares worth $13.52 million over the past 90 days, and lead candidate ONCT-01 remains in Phase 1 trials for advanced solid tumors.

Bank of New York Mellon Corp purchased a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 140,870 shares of the company's stock, valued at approximately $13,407,000. Bank of New York Mellon Corp owned about 0.23% of Oruka Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ORKA. Royal Bank of Canada raised its stake in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after acquiring an additional 365 shares during the last quarter. Kennedy Capital Management LLC raised its holdings in shares of Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company's stock worth $1,476,000 after purchasing an additional 420 shares during the last quarter. AlphaCentric Advisors LLC lifted its position in Oruka Therapeutics by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company's stock valued at $564,000 after purchasing an additional 626 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Oruka Therapeutics by 35.0% during the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company's stock valued at $92,000 after buying an additional 788 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Oruka Therapeutics in the 4th quarter valued at about $37,000. Institutional investors and hedge funds own 56.44% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Weiss Ratings upgraded Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 15th. Wedbush reaffirmed an "outperform" rating and set a $165.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Wall Street Zen cut shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. Guggenheim restated a "buy" rating and set a $200.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, UBS Group lifted their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a "buy" rating in a research note on Wednesday, July 1st. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Oruka Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $134.30.

Oruka Therapeutics Trading Down 0.6%

ORKA stock opened at $92.11 on Wednesday. Oruka Therapeutics, Inc. has a 12-month low of $14.66 and a 12-month high of $115.51. The business's 50-day moving average is $94.92 and its 200 day moving average is $68.59. The stock has a market cap of $6.10 billion, a price-to-earnings ratio of -45.37 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). As a group, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.33 EPS for the current fiscal year.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 10,000 shares of the firm's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total value of $1,066,600.00. Following the transaction, the senior vice president owned 15,312 shares in the company, valued at approximately $1,633,177.92. This trade represents a 39.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 75,000 shares of Oruka Therapeutics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the sale, the chief executive officer directly owned 925,580 shares in the company, valued at approximately $84,996,011.40. This trade represents a 7.50% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 158,116 shares of company stock valued at $13,523,783 in the last 90 days. 23.49% of the stock is owned by company insiders.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

Want to see what other hedge funds are holding ORKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source